

Joanne S Haviland

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/348580/publications.pdf>

Version: 2024-02-01

60
papers

5,054
citations

201575

27
h-index

155592

55
g-index

63
all docs

63
docs citations

63
times ranked

3996
citing authors

#	ARTICLE	IF	CITATIONS
1	The UK Standardisation of Breast Radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10-year follow-up results of two randomised controlled trials. <i>Lancet Oncology</i> , The, 2013, 14, 1086-1094.	5.1	1,141
2	Hypofractionated breast radiotherapy for 1 week versus 3 weeks (FAST-Forward): 5-year efficacy and late normal tissue effects results from a multicentre, non-inferiority, randomised, phase 3 trial. <i>Lancet</i> , The, 2020, 395, 1613-1626.	6.3	603
3	Effect of radiotherapy fraction size on tumour control in patients with early-stage breast cancer after local tumour excision: long-term results of a randomised trial. <i>Lancet Oncology</i> , The, 2006, 7, 467-471.	5.1	520
4	Partial-breast radiotherapy after breast conservation surgery for patients with early breast cancer (UK IMPORT LOW trial): 5-year results from a multicentre, randomised, controlled, phase 3, non-inferiority trial. <i>Lancet</i> , The, 2017, 390, 1048-1060.	6.3	448
5	First results of the randomised UK FAST Trial of radiotherapy hypofractionation for treatment of early breast cancer (CRUKE/04/015). <i>Radiotherapy and Oncology</i> , 2011, 100, 93-100.	0.3	226
6	Comparison of patient-reported breast, arm, and shoulder symptoms and body image after radiotherapy for early breast cancer: 5-year follow-up in the randomised Standardisation of Breast Radiotherapy (START) trials. <i>Lancet Oncology</i> , The, 2010, 11, 231-240.	5.1	201
7	Ten-Year Results of FAST: A Randomized Controlled Trial of 5-Fraction Whole-Breast Radiotherapy for Early Breast Cancer. <i>Journal of Clinical Oncology</i> , 2020, 38, 3261-3272.	0.8	175
8	The impact of age and clinical factors on quality of life in early breast cancer: An analysis of 2208 women recruited to the UK START Trial (Standardisation of Breast Radiotherapy Trial). <i>Breast</i> , 2007, 16, 241-251.	0.9	172
9	The UK HeartSpare Study: Randomised evaluation of voluntary deep-inspiratory breath-hold in women undergoing breast radiotherapy. <i>Radiotherapy and Oncology</i> , 2013, 108, 242-247.	0.3	163
10	Hypofractionated Whole-Breast Radiotherapy for Women With Early Breast Cancer: Myths and Realities. <i>International Journal of Radiation Oncology Biology Physics</i> , 2011, 79, 1-9.	0.4	142
11	A genome wide association study (GWAS) providing evidence of an association between common genetic variants and late radiotherapy toxicity. <i>Radiotherapy and Oncology</i> , 2014, 111, 178-185.	0.3	128
12	The course of anxiety and depression over 5 years of follow-up and risk factors in women with early breast cancer: Results from the UK Standardisation of Radiotherapy Trials (START). <i>Breast</i> , 2010, 19, 84-91.	0.9	86
13	Pre-Surgery Depression and Confidence to Manage Problems Predict Recovery Trajectories of Health and Wellbeing in the First Two Years following Colorectal Cancer: Results from the CREW Cohort Study. <i>PLoS ONE</i> , 2016, 11, e0155434.	1.1	80
14	Quality of Life and Experience of Care in Women With Metastatic Breast Cancer: A Cross-Sectional Survey. <i>Journal of Pain and Symptom Management</i> , 2012, 43, 747-758.	0.6	75
15	The UK HeartSpare Study (Stage IB): Randomised comparison of a voluntary breath-hold technique and prone radiotherapy after breast conserving surgery. <i>Radiotherapy and Oncology</i> , 2015, 114, 66-72.	0.3	72
16	Late normal tissue effects in the arm and shoulder following lymphatic radiotherapy: Results from the UK START (Standardisation of Breast Radiotherapy) trials. <i>Radiotherapy and Oncology</i> , 2018, 126, 155-162.	0.3	72
17	Large breast size as a risk factor for late adverse effects of breast radiotherapy: Is residual dose inhomogeneity, despite 3D treatment planning and delivery, the main explanation?. <i>Radiotherapy and Oncology</i> , 2011, 100, 236-240.	0.3	66
18	Patient-Reported Outcomes Over 5 Years After Whole- or Partial-Breast Radiotherapy: Longitudinal Analysis of the IMPORT LOW (CRUK/06/003) Phase III Randomized Controlled Trial. <i>Journal of Clinical Oncology</i> , 2019, 37, 305-317.	0.8	58

#	ARTICLE	IF	CITATIONS
19	Social support following diagnosis and treatment for colorectal cancer and associations with health-related quality of life: Results from the UK ColoRECTal Wellbeing (CREW) cohort study. <i>Psycho-Oncology</i> , 2017, 26, 2276-2284.	1.0	53
20	A Randomized Controlled Trial of Relaxation Training to Reduce Hot Flashes in Women with Primary Breast Cancer. <i>Journal of Pain and Symptom Management</i> , 2008, 35, 397-405.	0.6	51
21	Ipsilateral Breast Tumor Relapse: Local Recurrence Versus New Primary Tumor and the Effect of Whole-Breast Radiotherapy on the Rate of New Primaries. <i>International Journal of Radiation Oncology Biology Physics</i> , 2011, 79, 19-25.	0.4	49
22	Randomised phase II trial of hyperbaric oxygen therapy in patients with chronic arm lymphoedema after radiotherapy for cancer. <i>Radiotherapy and Oncology</i> , 2010, 97, 101-107.	0.3	42
23	FAST Phase III RCT of Radiotherapy Hypofractionation for Treatment of Early Breast Cancer: 10-Year Results (CRUKE/04/015). <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 102, 1603-1604.	0.4	40
24	Prolongation of overall treatment time as a cause of treatment failure in early breast cancer: An analysis of the UK START (Standardisation of Breast Radiotherapy) trials of radiotherapy fractionation. <i>Radiotherapy and Oncology</i> , 2016, 121, 420-423.	0.3	36
25	Hypofractionated Radiotherapy for Breast Cancer. <i>New England Journal of Medicine</i> , 2010, 362, 1843-1844.	13.9	34
26	Colorectal cancer patient's self-efficacy for managing illness-related problems in the first 2 years after diagnosis, results from the ColoRECTal Well-being (CREW) study. <i>Journal of Cancer Survivorship</i> , 2017, 11, 634-642.	1.5	34
27	Radiotherapy for breast cancer, the TARGIT-A trial. <i>Lancet, The</i> , 2014, 383, 1716-1717.	6.3	32
28	Conducting radiogenomic research – Do not forget careful consideration of the clinical data. <i>Radiotherapy and Oncology</i> , 2012, 105, 337-340.	0.3	28
29	Voluntary Breath-hold Technique for Reducing Heart Dose in Left Breast Radiotherapy. <i>Journal of Visualized Experiments</i> , 2014, , .	0.2	27
30	Test of association between variant $tg\beta 21$ alleles and late adverse effects of breast radiotherapy. <i>Radiotherapy and Oncology</i> , 2010, 97, 15-18.	0.3	19
31	The impact of dose heterogeneity on late normal tissue complication risk after hypofractionated whole breast radiotherapy. <i>Radiotherapy and Oncology</i> , 2012, 104, 143-147.	0.3	19
32	Ki67 Is an Independent Predictor of Recurrence in the Largest Randomized Trial of 3 Radiation Fractionation Schedules in Localized Prostate Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 101, 309-315.	0.4	19
33	Can patient-reported outcomes be used instead of clinician-reported outcomes and photographs as primary endpoints of late normal tissue effects in breast radiotherapy trials? Results from the IMPORT LOW trial. <i>Radiotherapy and Oncology</i> , 2019, 134, 220-230.	0.3	17
34	Pushing the limits of hypofractionation for adjuvant whole breast radiotherapy. <i>Breast</i> , 2010, 19, 176-179.	0.9	15
35	Smoking, alcohol consumption, diet and physical activity following stoma formation surgery, stoma-related concerns, and desire for lifestyle advice: a United Kingdom survey. <i>BMC Public Health</i> , 2019, 19, 574.	1.2	15
36	Impact of Hypofractionated Radiotherapy on Patient-reported Outcomes in Prostate Cancer: Results up to 5 years in the CHHiP trial (CRUK/06/016). <i>European Urology Oncology</i> , 2021, 4, 980-992.	2.6	14

#	ARTICLE	IF	CITATIONS
37	Hypofractionated Adjuvant Whole Breast Radiotherapy: Progress and Prospects. <i>Acta Oncologica</i> , 2010, 49, 1288-1292.	0.8	11
38	Cytokine levels as biomarkers of radiation fibrosis in patients treated with breast radiotherapy. <i>Radiation Oncology</i> , 2014, 9, 103.	1.2	11
39	Is breast seroma after tumour resection associated with patient-reported breast appearance change following radiotherapy? Results from the IMPORT HIGH (CRUK/06/003) trial. <i>Radiotherapy and Oncology</i> , 2019, 136, 190-196.	0.3	8
40	Targeted Intraoperative Radiotherapy for Early Breast Cancer. <i>JAMA Oncology</i> , 2020, 6, 1636.	3.4	8
41	Women's Free-text Comments on their Quality of Life: An Exploratory Analysis from the UK Standardisation of Breast Radiotherapy (START) Trials for Early Breast Cancer. <i>Clinical Oncology</i> , 2018, 30, 433-441.	0.6	7
42	A multicentre study of the evidence for customized margins in photon breast boost radiotherapy. <i>British Journal of Radiology</i> , 2016, 89, 20150603.	1.0	6
43	Quality of life after breast radiotherapy – Authors' reply. <i>Lancet Oncology</i> , The, 2010, 11, 612-613.	5.1	5
44	In Regard to Vaidya et al. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 92, 954-955.	0.4	4
45	Can patient decision aids reduce decisional conflict in a de-escalation of breast radiotherapy clinical trial? The PRIMETIME Study Within a Trial implemented using a cluster stepped-wedge trial design. <i>Trials</i> , 2021, 22, 397.	0.7	4
46	When the World Throws You a Curve Ball: Lessons Learned in Breast Cancer Management. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2021, 41, e79-e89.	1.8	3
47	Corrigendum to "The impact of age and clinical factors on quality of life in early breast cancer: An analysis of 2208 women recruited to the UK START Trial (Standardisation of Breast Radiotherapy)" <i>Journal of Clinical Oncology</i> , 2018, 36, 1743-1744.	1.0	3
48	Haste makes waste: Are the data regarding TARGIT-A IORT ready for prime time?. <i>Breast Cancer Research and Treatment</i> , 2014, 147, 221-222.	1.1	2
49	Does breast composition influence late adverse effects in breast radiotherapy?. <i>Breast</i> , 2016, 26, 25-30.	0.9	2
50	Internal mammary node irradiation in breast cancer: does benefit outweigh risk?. <i>Lancet Oncology</i> , The, 2020, 21, 1541-1543.	5.1	2
51	Abstract P6-12-04: Does the addition of a patient decision aid video reduce decisional conflict in patients considering a de-escalation of radiotherapy trial? Results from the PRIMETIME study. , 2020, , .		2
52	Late effects of breast radiotherapy. <i>Lancet</i> , The, 2014, 383, 1383-1384.	6.3	1
53	SP-0314: Partial breast radiotherapy after breast conservation: 5 year outcomes from the IMPORT LOW (CRUK/06/003) phase III trial. <i>Radiotherapy and Oncology</i> , 2017, 123, S162-S163.	0.3	1
54	Targeted radiotherapy for early breast cancer – Authors' reply. <i>Lancet</i> , The, 2018, 391, 27-28.	6.3	1

#	ARTICLE	IF	CITATIONS
55	OC-0156: Concordance of patient reported outcomes with clinician and photographic assessments in IMPORT LOW. Radiotherapy and Oncology, 2018, 127, S79.	0.3	1
56	Dose and fractionation regimens for breast cancer – Authors' reply. Lancet Oncology, The, 2006, 7, 619-620.	5.1	0
57	Corrigendum to –Randomised phase II trial of hyperbaric oxygen therapy in patients with chronic arm lymphoedema after radiotherapy for cancer–[Radiother Oncol 97 (2010) 101–107]. Radiotherapy and Oncology, 2011, 98, 285.	0.3	0
58	Breast cancer radiation therapy – Authors' reply. Lancet, The, 2020, 396, 1559-1560.	6.3	0
59	Assessment of Ki67 in relation to radiotherapy (RT) fractionation and prognosis in the CHHiP (CRUK/06/016) trial.. Journal of Clinical Oncology, 2018, 36, 98-98.	0.8	0
60	Abstract P6-12-10: Method development for a –Study within a Trial–™ using a cluster stepped wedge trial design: Evaluating a patient decision aid video on patients–™ decisional conflict in the PRIMETIME study. , 2020, , .		0